IMAP advises NuChem Sciences, a leading Canadian integrated Contract Research Organization, on its sale to UK-based Sygnature Discovery
NuChem, which employs 300 people in Montreal and Quebec City, Canada, is a leading North American contract research organization that offers integrated and standalone drug discovery services.
IMAP is pleased to announce that its team based in Montreal acted as exclusive financial advisor to NuChem Sciences (“NuChem”) on its sale to Sygnature Discovery (“Sygnature”).
NuChem, which employs 300 people in Montreal and Quebec City, Canada, is a leading North American contract research organization that offers integrated and standalone drug discovery services.
Sygnature, which employs over 1,000 people following this acquisition, is a leading UK-based contract research organization that offers integrated drug discovery services.
This acquisition creates a significant competitive advantage for Sygnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market and cements Sygnature as one of the world’s largest players in integrated drug discovery space servicing pharma, biotech, VCs and NFPs. This is the third in a series of acquisitions over the last sixteen months that have formed part of Sygnature’s global expansion, following the investment by Five Arrows, the alternative assets arm of Rothschild and Co, in Summer 2021.
The team from DNA Capital (IMAP Canada), led by Daniel Labrecque and Eric Ouellette, advised NuChem on the sale. This transaction is an excellent representation of their capability to execute structured and cross-border M&A transactions.